Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Oasmia Pharmaceutical AB - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Oasmia Pharmaceutical AB - Product Pipeline Review - 2014', provides an overview of the Oasmia Pharmaceutical AB's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Oasmia Pharmaceutical AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Oasmia Pharmaceutical AB including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Oasmia Pharmaceutical AB's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Oasmia Pharmaceutical AB's pipeline products Reasons to buy - Evaluate Oasmia Pharmaceutical AB's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Oasmia Pharmaceutical AB in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Oasmia Pharmaceutical AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Oasmia Pharmaceutical AB and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oasmia Pharmaceutical AB - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Oasmia Pharmaceutical AB and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Oasmia Pharmaceutical AB Snapshot 4 Oasmia Pharmaceutical AB Overview 4 Key Information 4 Key Facts 4 Oasmia Pharmaceutical AB - Research and Development Overview 5 Key Therapeutic Areas 5 Oasmia Pharmaceutical AB - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Oasmia Pharmaceutical AB - Pipeline Products Glance 9 Oasmia Pharmaceutical AB - Late Stage Pipeline Products 9 Pre-Registration Products/Combination Treatment Modalities 9 Phase III Products/Combination Treatment Modalities 10 Oasmia Pharmaceutical AB - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Oasmia Pharmaceutical AB - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Oasmia Pharmaceutical AB - Drug Profiles 13 paclitaxel 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 doxorubicin 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 docetaxel 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 OAS-19 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Oasmia Pharmaceutical AB - Pipeline Analysis 18 Oasmia Pharmaceutical AB - Pipeline Products by Target 18 Oasmia Pharmaceutical AB - Pipeline Products by Route of Administration 19 Oasmia Pharmaceutical AB - Pipeline Products by Molecule Type 20 Oasmia Pharmaceutical AB - Pipeline Products by Mechanism of Action 21 Oasmia Pharmaceutical AB - Recent Pipeline Updates 22 Oasmia Pharmaceutical AB - Dormant Projects 23 Oasmia Pharmaceutical AB - Locations And Subsidiaries 24 Head Office 24 Other Locations & Subsidiaries 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Oasmia Pharmaceutical AB, Key Information 4 Oasmia Pharmaceutical AB, Key Facts 4 Oasmia Pharmaceutical AB - Pipeline by Indication, 2014 6 Oasmia Pharmaceutical AB - Pipeline by Stage of Development, 2014 7 Oasmia Pharmaceutical AB - Monotherapy Products in Pipeline, 2014 8 Oasmia Pharmaceutical AB - Pre-Registration, 2014 9 Oasmia Pharmaceutical AB - Phase III, 2014 10 Oasmia Pharmaceutical AB - Phase I, 2014 11 Oasmia Pharmaceutical AB - Preclinical, 2014 12 Oasmia Pharmaceutical AB - Pipeline by Target, 2014 18 Oasmia Pharmaceutical AB - Pipeline by Route of Administration, 2014 19 Oasmia Pharmaceutical AB - Pipeline by Molecule Type, 2014 20 Oasmia Pharmaceutical AB - Pipeline Products by Mechanism of Action, 2014 21 Oasmia Pharmaceutical AB - Recent Pipeline Updates, 2014 22 Oasmia Pharmaceutical AB - Dormant Developmental Projects,2014 23 Oasmia Pharmaceutical AB, Subsidiaries 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.